JAJürgen Angerer

Jürgen Angerer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jürgen Angerer has a total of 59 co-authors. Here are the top co-authors by number of shared publications:

  • Hans Drexler

    Institute and Outpatient Clinic of Occupational, Social, and Environmental Medicine, Friedrich-Alexander University Erlangen-Nürnberg (IPASUM), Schillerstr. 25/29, 91054 Erlangen, Germany

    5 shared publications
  • Thomas Brüning

    3 shared publications
  • H. Drexler

    Institute and Outpatient Clinic of Occupational, Social and Environmental Medicine, University of Erlangen-Nuremberg, Erlangen, Germany

    2 shared publications
  • Heiko Udo Käfferlein

    Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Ruhr University Bochum, 44789 Bochum, Germany

    2 shared publications
  • Holger Martin Koch

    The University of Queensland 20 Cornwall Street

    2 shared publications
  • Jochen Hardt

    Clinic of Augsburg, Institute of Laboratory Medicine, Microbiology, and Environmental Hygiene, Augsburg, Germany

    2 shared publications

Latest Publications

  • Open Access

    Dermal Uptake and Excretion of 4,4′-Methylenedianiline during Rotor Blade Production in Helicopter Industry—An Intervention Study

    by Tobias Weiss, Hubert Schuster, Johannes MÜLler, Karl-Heinz Schaller, Hans Drexler, JÜRgen Angerer, Heiko U. KÄFferlein

    Objectives: Workers using composite materials by fibre reinforced laminate technology are exposed to 4,4′-methylenedianiline (MDA), a liver toxicant and suspected human carcinogen, during the production of rotor blades in helicopter industry. The aim of the study presented here was to assess the internal dose of MDA and the suitability of various personal protection measures at the workplace. Methods: Ambient monitoring and biological monitoring was carried out by analysing MDA in air and urine samples in seven workers of a highly specialized workplace (rotor blade production). Three different concepts of personal protection measures were applied to study the route of uptake and to evaluate strategies in decreasing workplace exposure. In addition, elimination kinetics of MDA was studied in three workers who were exposed to MDA on three consecutive working days. Results: Ambient monitoring consistently provided air levels at or below the limit of quantification of 0.1 μg m−3. Nevertheless, MDA was detected in 89% of all post-shift urine samples and median concentration was 4.2 μg l−1. MDA in urine were >20 times higher than expected on data from ambient monitoring alone. A significant decrease in exposure could be achieved when workers have worn MDA-protective overalls in combination with MDA-protective gloves and a splash protection shield (from 9.8 μg l−1 down to 3.7 μg l−1). The results show that MDA is taken up primarily via the skin at the workplaces under study. The excretion of MDA in urine was observed to be delayed after dermal exposure. Conclusions: Exposure assessment of MDA should be carried out by biological monitoring rather than ambient monitoring. For this purpose, urine samples midweek or at the end of the week should be used based on the observed delay in the excretion of MDA after dermal absorption. Uptake of MDA via the skin could not be completely avoided even if state-of-the-art personal protection measures were applied.


  • Current Relevance of New Biomarkers for Inclusion into HBM Surveillance Studies

    by Jürgen Angerer, Holger Koch, Ulrich Ewers, Jürgen Hölzer, Thomas Brüning, Michael Wilhelm

  • N-Acetyl-S-(1-carbamoyl-2-hydroxy-ethyl)-l-cysteine (iso-GAMA) a further product of human metabolism of acrylamide: comparison with the simultaneously excreted other mercaptuic acids

    by Eva C. Hartmann, Melanie I. Boettcher, Hermann M. Bolt, Hans Drexler, Jürgen Angerer

    The N-acetyl-S-(1-carbamoyl-2-hydroxy-ethyl)-l-cysteine (iso-GAMA) could be identified as a further human metabolite of acrylamide. In this study, we report the excretion of d3-iso-GAMA in human urine after single oral administration of deuterium labelled acrylamide (d3-AA). One healthy male volunteer ingested a dose of about 1 mg d3-AA which is equivalent to a dose of 13 μg/kg bodyweight. Over a period of 46 h the urine was collected and the d3-iso-GAMA levels analysed by LC-ESI-MS/MS. The excretion of iso-GAMA begins five hours after application. It rises to a maximum concentration (c max) of 43 μg/l which was quantified in the urine excreted after 22 h (t max). The excretion pattern is parallel to that of the major oxidative metabolite N-acetyl-S-(2-carbamoyl-2-hydroxy-ethyl)-l-cysteine (GAMA). Total recovery of iso-GAMA was about 1% of the applied dose. Together with N-acetyl-S-(2-carbamoylethyl)-l-cysteine (AAMA) and GAMA, 57% of the applied dose is eliminated as mercapturic acids. The elimination kinetics of the three mercapturic acids of AA are compared. We show that dietary doses of acrylamide (AA) cause an overload of detoxification via AAMA and lead to the formation of carcinogenic glycidamide (GA) in the human body.


  • Hemoglobin Adducts and Mercapturic Acid Excretion of Acrylamide and Glycidamide in One Study Population

    by Eva C. Hartmann, Melanie I. Boettcher, Thomas Schettgen, Hermann Fromme, Hans Drexler, Jürgen Angerer

    The aim of this study was to determine the relationship between the oxidative and reductive metabolic pathways of acrylamide (AA) in the nonsmoking general population. For the first time both the blood protein adducts and the urinary metabolites of AA and glycidamide (GA) were quantified in an especially designed study group with even distribution of age and gender. The hemoglobin adducts N-carbamoylethylvaline (AAVal) and N-(R,S)-2-hydroxy-2-carbamoylethylvaline (GAVal) were detected by GC-MS/MS in all blood samples with median levels of 30 and 34 pmol/g of globin, respectively. Concentrations ranged from 15 to 71 pmol/g of globin for AAVal and from 14 to 66 pmol/g of globin for GAVal. The ratio GAVal/AAVal was 0.4−2.7 (median = 1.1). The urinary metabolites were determined by LC-MS/MS. Of all urine samples examined 99% of N-acetyl-S-(2-carbamoylethyl)-l-cysteine (AAMA) levels and 73% of N-(R/S)-acetyl-S-(2-carbamoyl-2-hydroxyethyl)-l-cysteine (GAMA) levels were above the LOD (1.5 μg/L). Concentrations ranged from <LOD to 229 μg/L (median = 29 μg/L) for AAMA and from <LOD to 85 μg/L (median = 7 μg/L) for GAMA. The ratio of GAMA/AAMA varied from 0.004 to 1.4 (median = 0.3). Using hemoglobin adduct levels in blood and mercapturic acid excretion in urine for calculation of daily AA intake gave practically identical values. The median daily intakes were 0.43 (0.21−1.04) μg/kg of body weight(bw)/day using Hb adducts and 0.51 (<LOD−2.32) μg/kg of bw/day using mercapturic acids for calculations. Children take up approximately 1.3−1.5 times more AA per kilogram of body weight than adults. The ratio GAMA/AAMA is significantly higher in the group of young children (6−10 years) with a median level of 0.5. A gender-related difference in internal exposure and metabolism was not observed.


  • Risk assessment of workers exposed to fumes of bitumen: genotoxic effects and urinary metabolites of naphthalene, phenanthrene, and pyrene

    by Boleslaw Marczynski, Monika Raulf-Heimsoth, Heiko Udo Käfferlein, Katrin Förster, Anne Spickenheuer, Beate Pesch, Dietmar Breuer, Jürgen Angerer, Peter Welge, Rainer Bramer, et al.


  • Top Cited Papers

    Human biomonitoring: State of the art

    by Jürgen Angerer, Ulrich Ewers, Michael Wilhelm


  • Transplacental exposure of neonates to perfluorooctanesulfonate and perfluorooctanoate: a pilot study

    by O. Midasch, H. Drexler, N. Hart, M. W. Beckmann, J. Angerer

    Objectives Perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) can be released of perfluorinated compounds by biotic and/or metabolic decomposition. Due to their ubiquitous occurrence, persistence and bioaccumulative properties they can be found in blood of the general population all over the world. In animal studies PFOS and PFOA provoked cancer and showed developmental toxic potential besides other adverse health effects. On the basis of the comparison of maternal and umbilical cord plasma sample pairs we wanted to examine whether infants are exposed to PFOS and PFOA via their mothers’ blood. Methods We determined PFOS and PFOA in 11 plasma samples of mothers and the 11 corresponding cord plasma samples of neonates. An analytical method based on plasma protein precipitation followed by HPLC with MS/MS-detection was employed. As internal standards we used 1,2,3,4-13C4-PFOS and 1,2-13C2-PFOA. Results We found PFOS and PFOA in every plasma sample analysed. In maternal plasma samples PFOS concentrations were consistently higher compared to those of the related cord plasma samples (median: 13.0 μg/l vs. 7.3 μg/l). In the case of PFOA we observed only minor differences between PFOA concentrations within the analysed sample pairs (median: 2.6 μg/l vs. 3.4 μg/l for maternal and cord plasma samples, respectively). Discussion For both substances a crossing of the placental barrier could be shown. For PFOS we observed a decrease from maternal to cord plasma concentrations by a factor of 0.41–0.80. To the contrary, PFOA crosses the placental barrier obviously unhindered. These findings show that neonates are exposed to PFOS and PFOA via their mothers’ blood. Given the current situation that only little is known about the consequences of PFOS and PFOA exposure in the early state of development of humans and the fact that in animal studies both substances showed developmental toxic effects further research regarding human health effects is indispensable.


  • Open Access

    Aluminosis – Detection of an almost forgotten disease with HRCT

    by Thomas Kraus, Karl Heinz Schaller, Jürgen Angerer, Ralf-Dieter Hilgers, Stephan Letzel

    The aim of this study was to investigate whether it is possible to detect high-resolution computed tomography (HRCT) findings in aluminium powder workers, which are consistent with early stages of aluminosis. 62 male workers from 8 departments of two plants producing aluminium (Al) powder were investigated using a standardized questionnaire, physical examination, lung function analysis, biological monitoring of Al in plasma and urine, chest X-ray, HRCT and immunological tests. Chronic bronchitis was observed in 15 (24.2%) of the workers, and four workers (6.5%) reported shortness of breath during exercise. HRCT findings in 15 workers (24.2%) were characterized by ill-defined centrilobular nodular opacities. Workers with ill-defined centrilobular nodular opacities had a lower vital capacity than workers who had no such HRCT-findings (90.9 % pred. vs. 101.8 % pred., p = 0.01). Biological monitoring in plasma and urine revealed higher internal exposure to Al in affected workers (33.5 μg/l plasma to 15.4 μg/l plasma, p = 0.01) and (340.5 μg/g creat. to 135.1 μg/g creat., p = 0.007). Years of exposure and concentration of aluminum in urine and plasma appear to be the best predictors for HRCT findings. Age and decreased vital capacity show borderline significance. We conclude that aluminosis is still relevant in occupational medicine. With HRCT it is possible to detect early stages of aluminosis and biological monitoring can be used to define workers at high risk.


  • Current external and internal exposure to naphthalene of workers occupationally exposed to polycyclic aromatic hydrocarbons in different industries

    by Ralf Preuss, Hans Drexler, Melanie Böttcher, Michael Wilhelm, Thomas Brüning, Jürgen Angerer

    Objectives: External and internal exposure to naphthalene was examined in the most important industries that are typically concerned with polycyclic aromatic hydrocarbon (PAH)-induced diseases (cancer). Furthermore, a control collective from the general population was investigated. Methods: External naphthalene was determined by personal air sampling (n=205). The internal exposure was examined by urinary metabolites 1-naphthol and 2-naphthol (n=277). Results: Highest median concentrations of naphthalene in air were found in converter infeed (93.2 μg/m3) and coal-tar distillation (35.8 μg/m3). Moderate and low levels were determined in coking plants (14.5 μg/m3) and in the production of refractories (6.1 μg/m3) and graphite electrodes (0.7 μg/m3). Biological monitoring revealed concentrations of the sum of both metabolites [(1+2)-NOL] in smokers to be increased by 1.6–6.4 times compared with that in non-smokers at the same workplaces. Among non-smokers we found high median (1+2)-NOL levels in converter bricklayers (120.1 μg/l), in coal-tar distillation workers (56.0 μg/l) and in coking plant workers (29.5 μg/l). (1+2)-NOL concentrations around 10 μg/l were found in the production of refractories and graphite electrodes. There was a rough coherency between external and internal naphthalene exposure. In the controls, median (1+2)-NOL concentrations were 10.9 μg/l in non-smokers’ urine and 40.3 μg/l in smokers’ urine samples. Conclusions: Actual conditions of occupational hygiene at the workplaces investigated in this comprehensive study are better than those that current limit values of 50,000 μg/m3 (TLV, TRK) seem to induce. It has become obvious that tobacco smoking is a crucial confounding factor in biological monitoring of naphthalene-exposed humans, making interpretation of occupationally increased naphthol excretions very difficult at low exposure levels.


  • Nukleobasen‐Addukte von PAH im Humanurin

    by Albrecht Seidel, Jürgen Angerer